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EditorialLiving donor liver transplantation for HCV: Will the true
outcomes stand up?
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Center for Liver Disease and Transplantation, Columbia University College of Physicians and Surgeons, New York, NY, USASee Article, pages 1228–1243Hepatitis C (HCV) remains the most common indication for liver
transplantation. Early data suggested that patients with HCV that
received a living donor liver transplantation (LDLT) had worse
outcomes, including increased rates of cholestatic HCV than did
recipients of dead donor liver transplantation (DDLT) [1,2]. These
early studies have attributed the increase in graft failure in LDLT
recipients to more rapid HCV progression in the regenerating
LDLT graft. Several in vitro studies suggest that dividing hepato-
cytes are more vulnerable to HCV infection. This could lead to
increased levels of viremia, which is seen in cholestatic HCV, in
LDLT recipients. This also may have been due to an increased rate
of biliary complications or other problems seen during the learn-
ing curve of early LDLT experience. It was thought that biliary
complications were synergistic in their adverse impact on HCV
outcomes, but this has not been supported by subsequent data
[3].
More recent data suggests that there is no difference in recur-
rent HCV between recipients of DDLT and LDLT. These studies
were often based on protocol biopsies, were larger, and included
a later experience with LDLT. In a study of 23 LDLT recipients and
53 DDLT, protocol biopsies at 6 and 12 months were compared
for inﬂammation and ﬁbrosis and there was no difference in
mean inﬂammation scores or ﬁbrosis at any of the time points
measured [4]. 21% of the recipients of DDLT suffered acute rejec-
tion compared to 14% of the LDLT recipients; this difference was
not statistically signiﬁcant. Graft and patient survival rates
between the two groups were similar: at 48 months, 82 and
82% for DDLT patients and 76 and 79% for LDLT patients
(p = n.s.). Results from this study, which looked at liver histology,
do not support the idea that recurrent HCV is more prevalent
among recipients of LDLT. Additional studies including those
from the UNOS database and the NIH-sponsored Adult-to-Adult
Living Donor Liver Transplant Cohort Study (A2ALL) have alsoJournal of Hepatology 20
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recipients of LDLT [5,6].
The A2ALL data on HCV comparing 181 HCV positive LDLT
recipients to 94 HCV positive DDLT recipients showed similar
patient survival but lower 3-year graft survival in LDLT recipients
than in DDLT recipients (68% compared to 80% p = 0.04) [6]. How-
ever, center experience was a confounder of the relationship
between donor type and outcome. Once the center had per-
formed 20 cases, graft survival was equivalent between DDLT
and LDLT. For LDLT <20, 3-year graft survival was only 55% com-
pared to 79% and 80% for LDLT >20 and DDLT recipients, respec-
tively. There was equivalent and excellent patient survival
between LDLT >20 and DDLT as well, 91% and 87%, respectively.
Unfortunately, the majority of patients studied in the retrospec-
tive arm of the A2ALL group did not have protocol liver biopsies.
Of the 63 patients who were biopsied, there was no difference in
total necroinﬂammatory or ﬁbrosis scores between DDLT and
LDLT at one-year post-transplant.
As a result of this conﬂicting data, the role of LDLT in the man-
agement of patients with HCV has remained controversial. In an
attempt to synthesize prior data and illuminate the issue, Hu
et al. perform a meta-analysis of retrospective and prospective
studies looking at outcomes for living donor vs. a deceased donor
liver transplantation in this issue of the Journal of Hepatology.
They excluded large database analyses, including the UNOS data-
base, though the UNOS dataset was included in sensitivity analy-
ses. They also attempt to control for the heterogeneity of patients
by doing various sensitivity analyses including controlling for the
presence of HCC, donor age, and the era of transplantation. Over-
all, they ﬁnd no difference in patient survival and a trend towards
a lower graft survival in LDLT recipients at early time points post-
transplant, although this is not a consistent ﬁnding. Speciﬁcally,
LDLT patients have lower one and three-year graft survival, but
equivalent two, four, and ﬁve-year survival. The results answer
some questions but leave others unclear. Particularly, where does
this leave us in the controversial area of LDLT for HCV? I think it
is clear that patient survival rates from the time of transplant are
no better for a living donor transplantation, but they appear to be
no worse.
Second, there continues to be marked heterogeneity in the
patients selected for LDLT and they systematically differ from
those selected for DDLT leading to systematic biases that12 vol. 57 j 1166–1167
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confound comparisons. For example, the rate of HCC was signiﬁ-
cantly higher in the living donor group and these patients had a
worse outcome. Adjusting for these differences in the analysis
phase may not completely remove potential confounding.
Some of the differences in the outcomes for LDLT vs. DDLT is
likely independent of the type of transplant and may reﬂect the
fact that patients who have high risk of dying on the waiting list
or increased risk of poor post-transplant outcome may pursue
living donation, as it is their only option.
Finally, the meta-analysis does not include the pre-transplant
beneﬁt of pursuing LDLT which has been clearly demonstrated in
A2ALL and other studies [7,8]. Given the large sample size in this
meta-analysis, one would expect a consistent and statistically
signiﬁcant difference at all time points if a true signiﬁcant differ-
ence in patient or graft survival was present. Given the number of
patients included, my power calculation shows a 90% power to
detect a 5–6% difference in patient and/or graft survival. The
inconsisitent ﬁndings in graft survival raise questions as to
whether any true difference exists. Additionally, the heterogene-
ity between studies and the LDLT and DDLT cohorts points to the
need for more careful and detailed analyses of HCV recurrence
including the analysis of serial protocol liver biopsies. This data
should be forthcoming from the A2ALL study, and similar efforts
in the European Registry should be undertaken. In the meantime,
I think we can continue to conclude that LDLT does not offer a
signiﬁcant disadvantage to our patients in terms of post-trans-
plant outcome that will counteract the clear pre-transplant ben-
eﬁts in terms of reducing the waiting list mortality. As better
methods for viral eradication are developed pre and post-trans-
plant, the outcome of LDLT for our HCV positive patients should
increase. With these clinical improvements in HCV therapy, I
expect an increase rather than a decrease in the use of LDLT asJournal of Hepatology 2012a therapeutic modality for HCV patients awaiting liver
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